Geoffroy Pineau-Valencienne

Partner

París + 33.1.56.59.39.39

Contacto:

Compartir

Geoffroy Pineau-Valencienne has extensive experience in venture capital, private equity, M&A, and capital markets transactions. He represents a large number of private and public companies at every stage of development, from entrepreneurial start-ups to global corporations, particularly in the life sciences and technology fields, as well as financial and industrial investors.

Geoffroy's recent experience includes representation of technology and life sciences companies such as Amoéba, Amolyt Pharma, BonitaSoft, Cellectis, Criteo, Enertime, Eurobio, Genticel, Inotrem, Mathym, Mauna Kea Technologies, Talend, and Trace One. His recent investor-side representations include: AbbVie, Alven, Andera, Balderton, BioMed, Bpifrance, Breega, CTI Life Sciences, Elaia, Havenrock, HI Inov, Idinvest, Kurma, Novo Holdings, Partech, Regenxbio, Riverside, Serena, Seventure, Sofinnova Partners, Supernova, Ventech, Wellington, and Western Digital.

Illustrative examples of the transactions in which Geoffroy acted as lead lawyer include venture capital financings, either on issuer- or investor-side (in connection with the financing rounds of Alice & Bob, Amolyt Pharma, Alédia, CorWave, Domain Therapeutics, Inotrem, Masteos, MadBox, May Health, Mutabilis, Lendix, UpMem, UroMems, TriCares, and Vulkam), private and public M&A transactions ($1.05 billion acquisition of Amolyt Pharma by AstraZeneca, acquisition of Pipplet by ETS Global; sales of Alizé Pharma to Millendo, Mathym to Baikowski, Endocontrol to Canady Life Sciences, and SoCloz to Savoye; and the reverse merger of Genticel to Genkyotex), and IPOs and follow-on offerings (Amoéba, Genticel, and Enertime on the main or Growth market of Euronext Paris and Cellectis and Talend on Nasdaq).

Experiencia

  • Orphelia Pharma sells company to OrphalanJones Day advised Orphelia Pharma, a French pharmaceutical company dedicated to rare and serious pediatric diseases, particularly in neurology and oncology, and its shareholders in the sale of the company to Orphalan, a global pharmaceutical company specializing in the development and commercialization of orphan drugs.
  • Bpifrance (SPI 2 – Sociétés de Projets Industriels 2) participates in €21 million Series A financing of HyPrSpaceJones Day advised Bpifrance, through its SPI 2 – Sociétés de Projets Industriels 2 fund, in the €21 million Series A financing of HyPrSpace, a French industrial company providing suborbital and orbital launch services powered by a patented hybrid propulsion technology, co-led by Red River West and the DeepTech 2030 fund.
  • Bpifrance, Cap Horn and KBC invest €15 million in financing of HumminkJones Day advised Bpifrance, Cap Horn and KBC in connection with the €15 million financing of Hummink, a French start-up specialized in the development of methods, equipment and reagents for the deposition of sub-millimetric scale of materials on surfaces.
  • Bpifrance leads €43 million Series B financing of LATTICE MEDICALJones Day advised Bpifrance, through its SPI 2 fund, in the €43 million Series B financing of LATTICE MEDICAL, a French Medtech company specializing in tissue engineering, enabling the company to accelerate the clinical development of its MATTISE medical device, a breakthrough innovation in post-cancer breast reconstruction.
  • Bpifrance and HarbourView Equity Partners invest in AnimajJones Day advised Bpifrance S.A. and HarbourView Equity Partners as lead investors in the €75 million financing of Animaj, a next-generation media company that brings high-quality and inspiring brands to kids and families worldwide.
  • Bpifrance invests in ExpliseatJones Day advised Bpifrance as lead investor in the €36 million financing of Expliseat, a manufacturer of aircraft seats, alongside Crédit Mutuel Innovation, Supernova Invest and Swen Capital.
  • Bpifrance invests in ElkedoniaJones Day advised Bpifrance as co-lead investor in the €11.25 million seed financing of Elkedonia SAS, a pioneer in the development of therapeutic neuroplastogens to treat depression and other neuropsychiatric diseases.
  • Elaia Partners, Bpifrance (Digital Venture), Supernova Invest, and Breega participate in €100 million Series B financing of Alice & BobJones Day advised Elaia Partners, Bpifrance (Digital Venture), Supernova Invest, and Breega in connection with their participation in the €100 million Series B financing of Alice & Bob, led by Future French Champions, AVP (AXA Venture Partners), and Bpifrance (Deep Tech and Innovation Défense) for accelerating its path to build the world's first useful quantum computer.
  • Amolyt Pharma acquired by AstraZenecaJones Day advised Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, in its $1.05 billion acquisition by AstraZeneca.
  • Trill Impact Ventures and Bpifrance co-lead $25 million financing of May HealthJones Day advised Trill Impact Ventures and Bpifrance as lead investors in the $25 million Series B financing of May Health, a French-American medical device company targeting Polycystic Ovary Syndrome (PCOS) related infertility.
  • Bpifrance, INCO Ventures and SEB Alliance invest in VulkamJones Day advised Bpifrance, INCO Ventures and SEB Alliance in the €34 million financing of Vulkam, a deeptech company whose mission is to revolutionize metallurgy through the industrial development of amorphous metals.
  • Cortec Group sells Chauvet & Sons to Court Square Capital PartnersJones Day advised Cortec Group in the sale of its Chauvet & Sons platform to Court Square Capital Partners.
  • Bpifrance (SPI fund) participates in €61 million Series C financing of CorWave, together with other investorsJones Day advised Bpifrance (SPI fund) in connection with the €61 million Series C financing of CorWave, a high-tech medical devices company that has developed a next-generation heart pump based on a breakthrough technology, the wave membrane pump, together with other investors.
  • DIC acquires photoresist polymers manufacturer PCAS CanadaJones Day advised DIC Corporation, a Japanese chemicals group operating globally in over 60 countries, in connection with its acquisition of Quebec-based PCAS Canada Inc., a company that manufactures and sells polymers used in photoresists for semiconductor photolithography, from PCAS S.A., a French company.
  • Bpifrance (SPI fund), GoCapital and NCI invest in ExpliseatJones Day advised Bpifrance (SPI fund), GoCapital and NCI in the €17 million Series B financing of Expliseat, a company specializing in the design and manufacture of innovative lightweight seat technology.
  • Amolyt Pharma enters research agreement and licensing option with XOMAJones Day advised Amolyt Pharma, a global company specialized in developing innovative therapies for rare endocrine and related diseases, in the research agreement and licensing option with XOMA Corporation for the pre-clinical evaluation of a select set of monoclonal antibodies that arose from XOMA’s legacy discovery efforts as potential treatments for primary hyperparathyroidism and humoral hypercalcemia of malignancy. Amolyt has the option to license one or more of these candidates from XOMA for further clinical development worldwide.
  • Amolyt Pharma raises $138 million in Series C financingJones Day advised Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, in connection with its $138 million Series C financing led by Sofinnova Partners and co-led by Intermediate Capital Group (ICG), along with Tekla Capital Investment LLC, and CTI Life Sciences as well as existing investors, including, Andera Partners, Kurma, Bpifrance (Innobio), Sectoral, and Pontifax.
  • Eurobio Scientific acquires GenDxJones Day advised Eurobio Scientific SA in the acquisition and financing of the Dutch company Genome Diagnostics BV (GenDx) from its founder and its shareholders for €135 million (net of adjusted cash).
  • Omnes Capital leads $10 million financing round of WhiteLab GenomicsJones Day represented Omnes Capital as a lead investor in connection with the $10 million financing round of WhiteLab Genomics, a Y-Combinator backed AI-powered predictive software simulation platform for the design of gene and cell therapies.
  • Masteos raises €40 million in Series A financing roundJones Day advised Masteos SAS, a French tech company that provides advice and support services in real estate acquisition, renovation, and rental investment, in connection with its €40 million Series A financing round led by DST Global Partners with Daphni also participating.
    •

    Antes del envío, por favor tenga en cuenta:

    la información contenida en www.jonesday.com es para uso general y no constituye asesoramiento legal. El envío y recepción de este correo electrónico no pretenden crear una relación abogado-cliente. La información que envíe a cualquier persona de nuestra Firma no tendrá carácter confidencial o privilegiado excepto en el caso de que estemos actúando en su representación. Si envía este correo electrónico, confirma que ha leído y comprendido este aviso.